Intertek's Assurance in Action Podcast Network
Intertek's Assurance in Action Podcast Network
The GRAS Reality Check
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
What could the FDA’s proposed mandatory GRAS notification rule mean for your products and regulatory strategy? In this episode of GRAS Reality Check, Intertek Assuris experts Dennis Ashford and Rebekah Morrow discuss potential impacts on existing GRAS conclusions, food contact materials and legacy data.
Listen now to learn why reviewing your portfolio today can help you identify gaps and make informed, strategic decisions before the rule is finalized.
Presenters:
- Rebekah Morrow — Director, Regulatory Notifications, Intertek Assuris
- Dennis Ashford, PhD — Manager, Staff Scientist, Intertek Assuris
Follow us on- Intertek's Assurance In Action || Twitter || LinkedIn.
00:14 --> 00:33
Speaker 1 – Dennis Ashford, Manager, Senior Consultant, Staff Scientist, Intertek
All right, welcome everyone.
This is the GRAS Reality Check, an Intertek Assuris podcast. My name is Dennis Ashford. I'm a manager and staff scientist with Intertek Assuris. And today I'm joined by my colleague, Rebekah Morrow, who is the Director of Regulatory Notifications.
Rebekah, thanks for joining me today.
00:33 --> 00:36
Speaker 2 – Rebekah Morrow, Director, Regulatory Notifications and Compliance, Intertek Assuris
Thanks, Dennis. It's good to be here.
00:36 --> 01:06
Speaker 1 – Dennis Ashford, Manager, Senior Consultant, Staff Scientist, Intertek
Yeah, so today we're going to be talking about the FDA's proposed mandatory GRAS notification rule.
And as you can expect and know, there's been a lot of discussion about this potential rule and what it can mean for existing GRAS conclusions, especially those ones that are self-determined. And in particular, how does it translate to food contact materials.
So, before we get into the details, Rebekah, would you mind kind of just giving me a big picture view of what the FDA is actually proposing here?
01:06 --> 02:44
Speaker 2 – Rebekah Morrow, Director, Regulatory Notifications and Compliance, Intertek Assuris
Yeah, so the most important thing to understand is that this is still a proposed rule. It's not final yet, and it could be modified or maybe even withdrawn. But fundamentally, FDA is proposing to change the role of notification for certain independently determined GRAS conclusions.
Under the current framework, a company can make an independent GRAS conclusion without necessarily notifying FDA. Notifications have generally been voluntary, and this proposal would generally require notification to FDA for certain self-determined GRAS conclusions.
So, what it doesn't do is eliminate the underlying GRAS framework. So, companies could still make an independent GRAS conclusion based on the appropriate scientific information. So, the fundamental scientific question remains, is the substance safe under its intended conditions of use? And is that conclusion supported by the appropriate scientific information?
The potential change is that companies may have a new obligation to notify FDA about that conclusion. And that kind of creates a very practical question for companies, if notification does become required, do we have the information necessary to support that notification? And that is particularly important when we start talking about older or legacy GRAS conclusions.
So, Dennis, from your perspective as a scientist and an analytical expert, why do you think companies should be concerned about some of these older GRAS dossiers?
02:44 --> 04:06
Speaker 1 – Dennis Ashford, Manager, Senior Consultant, Staff Scientist, Intertek
Yeah, so I mean, the biggest issue with these, especially older GRAS dossiers, is the fact that the material and or the supporting information really could have changed over time.
So, you could imagine a company that has a conclusion that was developed many years ago. I mean, this could be decades ago. And we're kind of asking today, whether that actual information and data represents the way that the material is used today.
So that could be, has the manufacturing process changed? Has the raw materials changed? Has the specifications or the impurity profile changed? De the original analytical or toxicology conclusions reflect the current scientific understanding of that material?
And another one that we see somewhat often for these legacy materials is the use case. Is the use case change? Is it used more? Is it used in a different application, differen t conditions of use?
These are the things that, you know, really companies should start asking themselves what this proposed rule that's coming through the FDA. So, does the current product and current use still match the scientific basis of the original GRAS conclusion?
If you kind of think about what companies should really start looking at now, you know, Rebekah, the rule isn't final yet, why should companies be doing anything now? Why not simply wait and see if the FDA ultimately does something with this.
04:06 --> 05:42
Speaker 2 – Rebekah Morrow, Director, Regulatory Notifications and Compliance, Intertek Assuris
Yeah, yeah, exactly.
That's a reasonable question. And, you know, we're not suggesting that companies should immediately begin filing notifications or launching major testing programs.
The reason really to start now is portfolio visibility. So, companies should understand what regulatory conclusions they have what regulatory pathways support those conclusions, and where the potential gaps are.
The concern is, the concern with waiting until the proposed ruling is final is that documentation can become increasingly difficult to reconstruct. Supporting studies may be difficult to locate. In some cases, employees who understood the original regulatory strategy may have left the company. Supplier changes may not be fully documented, and historical data may no longer be representative of the current product.
The real benefit here of starting now is not that you necessarily need to make a regulatory decision today, but it's that you have time to understand your options before a final rule creates a deadline.
As we said in our presentation that we did earlier this month, companies that begin reviewing their portfolios now have greater flexibility to make strategic decisions rather than reactive ones.
So, thinking about where a company should start, Dennis, let's say a company decides it wants to assess its portfolio. Where would you start from an analytical and scientific perspective?
05:42 --> 07:18
Speaker 1 – Dennis Ashford, Manager, Senior Consultant, Staff Scientist, Intertek
Yeah, and it's really important to just kind of start with the basics.
You know, first you want to identify the substances and confirm its identity and composition, these materials that may be impacted by this rule.
And then looking at the manufacturing and the specifications, understanding the raw materials, the manufacturing process and the potential impurities.
Then start to look at the analytical method and data that was used to draw the original GRAS conclusions.
So, you know, you can be asking the type of questions of, are these methods still appropriate? Are the standards still available? Is this testing still available? Are the detection limits appropriate for the current regulatory questions being asked? And again, most importantly, does that data actually represent the material being used and manufactured today?
From food contact material perspective, I would I really want to understand what the migration and dietary exposure is to the consumers of that material.
And if the product formulation or the manufacturing process or the feedstocks or really anything in the downstream or upstream application of that material, has it changed from those original GRAS conclusions.
So again, we don't automatically want to start generating a bunch of new data. We first want to determine what we already have and whether it is still fit for the purpose of use.
If we kind of think about, you know, Rebekah, from the regulatory perspective, what do you think companies should be looking at while they're reviewing that scientific information from the regulatory side.
07:18 --> 08:58
Speaker 2 – Rebekah Morrow, Director, Regulatory Notifications and Compliance, Intertek Assuris
Yeah, so I think I'd start with one pretty basic question, and that's why is this product legally marketed today?
And sometimes that's not as obvious as you might think, you know, but some questions to kind of ask yourself are, you know, is it based on an independent GRAS conclusion? or a GRAS notification? or a food additive regulation? an FCN? a threshold of regulation or TOR exemption? Is it prior sanctioned or, you know, does it have some other regulatory basis?
Those distinctions really matter because these pathways are not interchangeable, then I would compare the original regulatory basis with the product as it exists today.
Some additional questions to ask yourself is, what is the current intended end use application? What are the use levels? What are the conditions of use? Has the product changed in any way? And has the regulatory landscape changed?
Then ultimately, the question to ask yourself is, is the original regulatory pathway still the most appropriate pathway for the product? And that's an important question because companies shouldn't necessarily assume that the regulatory strategy that was selected many years ago, you know, as you mentioned, even decades ago, is still the best strategy today.
So then, you know, kind of thinking about...why food contact materials are different. Maybe, Dennis, let's focus on specifically on food contact materials and why does the proposed rule create some additional considerations for packaging companies?
08:58 --> 10:04
Speaker 1 – Dennis Ashford, Manager, Senior Consultant, Staff Scientist, Intertek
Yeah, and it really has to do with the fact that these food contact assessments can involve a very different type of analytical evaluation to, say, a food additive.
When it comes to food contact, we're most often concerned with migration. And their question is really is how much of that substance or its impurities or residuals are reaching the food, which ultimately reaches the diet of the consumer.
And again, we're asking ourselves, what's the relevant conditions of use? What are the potential migrants? What impurities or degradation products can be present? And are we adequately characterizing these substances analytically? And again, that could be from a detection limit standpoint or just a method. We need to ensure that these methods are properly validated and we are analyzing everything or quantifying everything that's inside that substance and mixture.
So you can have a substance with a very well-developed toxicology history, but in the food contact application is substantially different from what was previously considered. So, you may need to have a new exposure assessment and question to ask yourself.
10:04 --> 10:26
Speaker 2 – Rebekah Morrow, Director, Regulatory Notifications and Compliance, Intertek Assuris
Yeah, exactly. And that's why one of the key messages for food contact companies is that GRAS is not the same thing as food contact clearance. For food contact applications, migration, exposure, conditions of use, and the applicable FDA authorization pathway can all become important considerations.
10:26 --> 10:38
Speaker 1 – Dennis Ashford, Manager, Senior Consultant, Staff Scientist, Intertek
Yeah, yeah.
And so, you know, if you kind of think about it, if a company has a substance that currently relies on an independent GRAS conclusion, are they necessarily just looking at a GRAS notification then if this rule goes into effect?
10:38 --> 12:20
Speaker 2 – Rebekah Morrow, Director, Regulatory Notifications and Compliance, Intertek Assuris
No, not necessarily.
That's where this becomes a strategic regulatory decision.
One option might be to reassess the existing GRAS conclusion and determine whether the current science and intended end use still support or can still be supported.
The proposed rule also includes a potential streamlined pathway for certain instances that are already marketed under independent graphs conclusions. And that pathway would be a time limited and more importantly, included on an FDA public list. But it would not mean that FDA, it would not necessarily mean that FDA had reviewed it and then agreed with the GRAS determination.
A company could also consider a full GRAS notification where that makes sense.
And for food contact uses, there may be other options. So, for certain low exposure food contact uses, a threshold of regulation or TOR exemption pathway might be appropriate.
And then depending on the substance and application, a food contact notification may be another potential pathway that you would want to explore.
So the goal shouldn't really be how do we turn every existing GRAS conclusion into a notification. The goal should be what regulatory pathway makes the most sense for this particular substance, this particular use, the data package that we have, and the business objective
So maybe Dennis, let's maybe talk about TOR as an example. So what role does analytical data play if a company is considering a threshold of regulation strategy?
12:20 --> 13:13
Speaker 1 – Dennis Ashford, Manager, Senior Consultant, Staff Scientist, Intertek
Yeah, so TOR is an interesting one because the analytical is critical, even though, you know, a lot of times people tend to think TOR is pretty straightforward because it's low exposure. But, you know, with a TOR, and especially for food contact use, you do need to have reliable information about
migration and exposure of these materials.
I think it's important not to oversimplify this just to a single migration number. Again, you really need to consider the applicable exposure criteria and toxicological considerations as well.
So, the analytical testing kind of needs to be designed around that regulatory question that you're asking there. You want to know what your migration data is representative and that the analytical methods are appropriate and the resulting exposure assessment is defensible for the material.
13:13 -->13:56
Speaker 2 – Rebekah Morrow, Director, Regulatory Notifications and Compliance, Intertek Assuris
Right, and that's also true when we're looking at an FCN or a food contact notification submission.
And so, for novel polymers, coatings, adhesives, functional barriers, recycled content technologies, and other emerging packaging technologies, migration and exposure assessments are also very critical.
But an FCN also has an important commercial characteristic, and that's because it is manufacturer specific, and it can provide confidentiality and competitive differentiation in the market that may be attractive for some of these more proprietary types of technologies.
13:56 --> 14:22
Speaker 1 – Dennis Ashford, Manager, Senior Consultant, Staff Scientist, Intertek
Yep, yep, exactly.
The FCM pathway makes a lot of sense, especially for these new and novel technologies that we see coming out, particularly in food contact, obviously.
So, you know, let's kind of make this practical and work towards wrapping this up. If a company wants to start preparing now, again, this is a proposed rule, but we do recommend that companies really start to think about this and start preparing. You know, what would you recommend that they start to do over the next 90 days?
14:22 --> 15:55
Speaker 2 – Rebekah Morrow, Director, Regulatory Notifications and Compliance, Intertek Assuris
Yeah, I mean, I think I'd go back to using that six-step framework that we included in the webinar that we hosted earlier this month. And that was, inventory, triage, verify, assess, decide, and execute.
You know, so first, inventory, the substances, products, intended uses, and the regulatory basis.
Then triage the portfolio kind of based on commercial importance, regulatory uncertainty, and any data gaps that might be identified.
After that, verify the current identity, the composition, specifications, manufacturing information, and end uses.
Then that assessment piece comes in where we want to assess the safety exposure, migration where relevant, and any supporting documentation.
Then next step would be to really decide which regulatory pathways may make the most sense and then execute A prioritized work plan.
The important point here is really that companies don't need to assume that every product will require the same level of effort, but they certainly don't need to assume that they should start testing everything today.
The goal is really to identify where the greatest regulatory uncertainty and business important kind of overlap.
So Dennis, maybe just let's finish with a few key takeaways. What's the biggest thing you want analytical and scientific teams to remember?
15:55 --> 16:54
Speaker 1 – Dennis Ashford, Manager, Senior Consultant, Staff Scientist, Intertek
Yeah, the biggest take away here at this point is it's best not to wait until you need to reproduce an old study and find out later that you can't for some reason, or that the data is not representative of the material or end use that you are currently working with.
So, it's really important to understand what analytical data you have, whether it represents the current material that's being manufactured, and whether the methods and supporting information are still appropriate to that.
And again, we don't want to generate data simply because we think the FDA may ask for it. We want to generate data because you understand the regulatory question you're trying to answer. And that's really important.
When we design these analytical studies, it's critical for us to understand that we know exactly what, say, the conditions of use are and what the goal is, because you can collect analytical data forever, you don't want to do that. We want to be as efficient as possible.
And then, you know, Rebekah, from your side, what would you say the biggest take away is from the regulatory side?
16:54 --> 17:34
Speaker 2 – Rebekah Morrow, Director, Regulatory Notifications and Compliance, Intertek Assuris
Yeah, so I think my biggest take away would be don't start with a filing right off the bat. Start with the regulatory basis.
So, understand why each important product is considered compliant today, then determine whether that basis still applies and whether it remains the best pathway going forward.
And remember that the proposed rule is not final. We're not necessarily recommending that companies assume the proposal will remain unchanged. We're really recommending that companies use this as an opportunity to understand their portfolios while they still have time to make strategic decisions.
17:34 --> 17:52
Speaker 1 – Dennis Ashford, Manager, Senior Consultant, Staff Scientist, Intertek
Yeah, it's a great point about using this as an opportunity to understand portfolios, because as we know, some of those portfolios are large, old, and all over the place. So, it's a good time to really bring those together.
You know, perhaps the most important question right now is, do we need to file something?
17:52 --> 18:00
Speaker 2 – Rebekah Morrow, Director, Regulatory Notifications and Compliance, Intertek Assuris19:29
No, it's really, I think, it's really, do we understand our regulatory position well enough to make that decision?
18:00 -->18:13
Speaker 1 – Dennis Ashford, Manager, Senior Consultant, Staff Scientist, Intertek
And that's kind of the whole point of this podcast is that's the GRAS reality check is what do we understand about our GRAS portfolio and where are these data gaps that we need to identify potentially in the future?
18:13 -->18:16
Speaker 2 – Rebekah Morrow, Director, Regulatory Notifications and Compliance, Intertek Assuris
And I'm Rebekah Morrow, and thank you for listening.
18:16 --> 18:18
Speaker 1 – Dennis Ashford, Manager, Senior Consultant, Staff Scientist, Intertek20:07
Yeah, thanks everyone.